drugset / Trial / NCT00198081

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

NCT00198081 ↗

Phase 2 Terminated 8 enrolled Indiana University
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.

Timeline

Start
2005-09
Primary completion
2012-04
Completion
2012-04

Outcome

Outcome not reported

Stopped (Business): “Lack of funding and personnel to conduct study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg —

Indications